Solid Biosciences Q3 2026 Results: Net Loss of $53.9M, Loss Widens
Solid Biosciences Inc. reported a significant increase in cash, cash equivalents, and available-for-sale securities, totaling approximately $348.9 million as of September 30, 2026, compared to $187.9 million at year-end 2025. The company's accumulated deficit grew to $1.12 billion, reflecting ongoing losses as it advances its neuromuscular and cardiac clinical candidates.
- Key figure
- Net loss $53.9M